ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Ra Med Electrophysiology Division Announces New Publication of Clinical Data

New Study Confirms Advantages of Using VIVO for Pre-Procedure Ventricular Ablation Planning

FORT MILL, SC / ACCESSWIRE / March 8, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has had new clinical data published for its leading product VIVO (View Into Ventricular Onset), that confirms the perceived benefits of using VIVO in a ventricular ablation program.

VIVO is a non-invasive localization system that provides the physician with data about the patient's heart prior to a ventricular ablation. This data is then used by the physician to plan certain aspects of the procedure including where to look for the start of the arrhythmia (often the target for the ablation), which can be a time-consuming process.

The newest publication (https://www.sciencedirect.com/science/article/pii/S0022073623000250) by the Royal Brompton Hospital (London, UK) with lead author Professor Sabine Ernst, confirms that VIVO does reduce mapping time by almost 30%. A reduction in mapping time leads to a total reduction in procedure time, potentially increasing patient safety. In addition, this publication discusses that patients with previous ablations that were unable to be performed were now able to have successful ablation procedures improving treatment options for patients with infrequent ventricular arrhythmias.

"We have seen for some time that using VIVO would have many benefits," said David Jenkins, CEO. "It is great to have data that shows how pre-procedure planning with VIVO can provide benefits not just to patients by reducing their time under anesthesia, but also improving the workflow for physicians. VIVO has the potential to allow additional procedures in the EP labs due to increased efficiency and reduce the amount of patient backlog. VIVO is showing tremendous potential to improve workflows and outcomes that help patients, physicians and hospitals."

Mr. Jenkins continued, "This publication joins a number of other publications and scientific presentations on the advantages of utilization of the VIVO technology within the hospital setting. Combined with almost 1,000 procedures performed to date with VIVO, the early experience is accelerating to what we believe will become widespread clinical acceptance and usage."

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company
David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical Systems, Inc.



View source version on accesswire.com:
https://www.accesswire.com/742477/Ra-Med-Electrophysiology-Division-Announces-New-Publication-of-Clinical-Data

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.